Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

Liminal BioSciences Inc. > I wonder what a judge would make of this?
View:
Post by aussyspitz on Apr 01, 2020 7:56pm

I wonder what a judge would make of this?

This is a cleaned up summation of an awesome post found on a Seeking Alpha that lays it out pretty well:

"SALP/(Consanance) debt at the time of the TSX hardship and restructure was shown as $229 million, It was previously $120 Million due in 2019 so how did they go from $120 Million to $229 Million in debt?  They had recently extended the loan to 2024 which at the time was taken as a relief which would resolve the balance sheet issue until revenue would start to flow from their pipeline. Looking back it was a move on the part of SALP (Consanance) to claim all of the unearned interest at the time of the restructure to be able to double the outstanding loan by taking another $109 million which means they received approximately 7.23 Billion shares for interest that was never earned. By extending the loan period out to 2024 for the planned pretext of claiming 5 years of interest at 10% per year for a period that the loan never existed for, and with the intent of using this as a pretext in order to collect about another 7.23 Billion shares resulting in an ownership grab of about 30% of the company. Additionally, they intentionally capped the rights offering to the retail investors at $75 Mil (about 4 Bil shares) while they themselves virtually took an extra 7.23 Billion shares and 30% control for non-earned interest.  However, the cherry on top is their strategic application to the TSX for a "hardship" case in order to put this through without allowing the shareholders a vote as they knew would have lost that vote." 

IMO Thomvest and SALP(Consanance) and their legal team literally fed retail investors to the wood chipper
Comment by StockReddy on Apr 02, 2020 3:36pm
Exactly! They robbed us (retail investers) and we buy back our own shares  at $ 15.24 and again lost almost half of it. What a pathetic story.  I don't know how the regulators can't understand this simole logic (unearned interest matter).
Comment by StockReddy on Apr 02, 2020 3:45pm
Exactly! They robbed us (retail investers) and we buy back our own shares  at $ 15.24 and again lost almost half of it. What a pathetic story.  I don't know how the regulators can't understand this simple logic (unearned interest matter).
Comment by PLITheOne on Aug 11, 2021 8:53am
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities